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Abstract 
The integrin 61 is a major laminin receptor, and formation of a laminin-rich basement 
membrane is a key feature in tumour blood vessel stabilisation and pericyte recruitment; 
processes that are important in the growth and maturation of tumour blood vessels. However, 
the role of pericyte 61-integrin in angiogenesis is largely unknown. We developed mice 
where the 6-integrin subunit is deleted in pericytes and examined tumour angiogenesis and 
growth. These mice had: i) reduced pericyte coverage of tumour blood vessels; ii) reduced 
tumour blood vessel stability; iii) increased blood vessel diameter; iv) enhanced leakiness and, 
v) abnormal blood vessel basement membrane architecture. Surprisingly, tumour growth, 
blood vessel density and metastasis were not altered. Analysis of retinas revealed that deletion 
of pericyte 6-integrin did not affect physiological angiogenesis. At the molecular level, we 
provide evidence that pericyte 6-integrin controls PDGFR expression and AKT/mTOR 
signalling. Together, we show that pericyte 61-integrin regulates tumour blood vessels by 
both controlling PDGFR and basement membrane architecture.  These data establish a novel 
dual role for pericyte 6-integrin that affects the blood vessel phenotype during pathological 
angiogenesis.   
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Introduction 
 
Blood vessels comprise of endothelial cells supported by mural cells, also known as pericytes. 
Although the role of integrins in endothelial biology has been studied extensively 
(Avraamides et al., 2008, Germain et al., 2010), almost nothing is known about the role of 
pericyte integrins, including 6-integrin (Garmy-Susini et al., 2005, Liu and Leask, 2012). 
Integrins are transmembrane cell surface receptors that mediate cell-cell and cell-extracellular 
matrix (ECM) interactions. One of the major components of the vascular basement membrane 
is laminin whose predominant adhesive receptors include integrins 61 and 64 (Durbeej, 
2010). Targeting endothelial integrins has proved to be relatively beneficial in treating cancer 
in preclinical studies (Yamada et al., 2006, Tabatabai et al., 2010) but has had limited success 
in clinical trials (Patel et al., 2001), therefore new targets, including pericytes are currently 
being examined. 
 
Tumour blood vessels have many structural abnormalities including decreased endothelial 
barrier function, reduced pericyte recruitment and poor basement membrane organisation 
when compared with normal, quiescent vessels (Armulik et al., 2005). Studies have shown 
that pericyte recruitment and investment to blood vessels stimulates endothelial cell basement 
membrane (BM) deposition and organisation in vitro (Stratman et al., 2009). This is mediated 
mainly by secretion of endothelial PDGF-BB, attracting PDGFR-positive pericytes which 
adhere to the BM surrounding endothelial cells (Stratman et al., 2010, Abramsson et al., 
2003). In vivo, mice lacking PDGF-BB/PDGFR signalling fail to adequately recruit 
pericytes to newly formed blood vessels resulting in severe perturbation of blood vessel 
stabilisation and maturation (Hellberg et al., 2010). Furthermore, interference with PDGF-
BB/PDGFR signalling results in disruption of already established endothelial/pericyte 
associations and vessel destabilisation during retinal development (Benjamin et al., 1998). 
Whether pericyte 6-integrin might regulate tumour vessel stability was hitherto unknown.  
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In the present study, we examined the role of pericyte 6-integrin on tumour blood vessel 
function using a genetic ablation approach. Surprisingly, loss of pericyte 6-integrin did not 
affect tumour growth, angiogenesis or metastasis but did cause a decrease in pericyte 
association with tumour blood vessels and poor basement membrane organisation, with an 
associated increase in vessel leakage and instability. At the molecular level, we demonstrate a 
novel mechanism by which pericyte 6-integrin reduces PDGFR expression on pericytes 
and therefore diminishes responses to PDGF-BB. This, in turn, is the likely mechanism for 
aberrant pericyte investment of tumour blood vessels. Together, our data suggest that pericyte 
61-integrin plays a dual role in regulating PDGFR expression and BM organisation that 
likely increases vessel leakage and instability.  
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Methods 
Generation of mice 
6-integrin floxed mice (Bouvard et al., 2012, Germain et al., 2010) were bred with mice 
expressing Cre-recombinase under the control of the Platelet Derived Growth Factor Receptor 
 (PDGFR) promoter, PDGFRCre (Foo et al., 2006) to generate pdgfrβcre-;6fl/fl and 
pdgfrβcre+;6fl/fl mice.  mTmG mice were obtained from Cancer Research UK.   
 
Immunostaining of tumour sections 
Unless otherwise stated, frozen sections were fixed in ice-cold acetone for 10 min followed 
by permeabilisation with 0.5% NP-40 for 10 min. Sections were blocked for 45 min with 
1.0% bovine serum albumin (BSA) and 0.1% Tween 20 in PBS. Primary antibodies were 
incubated overnight at 4C followed by incubation with a fluorescently conjugated secondary 
antibody for 1 h at room temperature (1:1000; Invitrogen). The following primary antibodies 
were used: 6-integrin (Chemicon GoH3), NG2 (Millipore AB5320), endomucin (Santa 
Cruz) (all 1:100).  
 
Quantitation of 6-integrin on pericytes 
Quantification of 6-integrin expression on NG2-positive pericytes on tumour blood vessels 
from pdgfrβcre-;6fl/fl and pdgfrβcre+;6fl/fl mice was performed using ImageJ™ software. 
The mean pixel intensity of 6-integrin expression on NG2-positive pericytes was quantitated.  
 
Immunostaining and quantitation of basement membrane 
Immunostaining for laminin 4 chain (kind gift from Takako Sasaki) was performed as 
described previously (Sasaki et al., 2001). For laminin 5 chain, sections were fixed in 4% 
paraformaldehyde (PFA), washed twice with PBS, then blocked with 1% BSA for 30 min. 
Sections were incubated overnight at 4°C with primary antibody (1:400 dilution in blocking 
buffer) (kind gift from Jeffrey H. Miner (Pierce et al., 2000)), followed by several washes, 
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incubation with Alexa 488-conjugated anti-rabbit secondary antibody (1:1000; Invitrogen) 
and mounted.  
For Collagen IV (Abcam) and Fibronectin (Abcam) staining, sections were fixed in 4% PFA, 
blocked with 3% NGS, 0.1% TritonX-100 (TX-100) in PBS for 30 min at room temperature. 
Primary antibody was diluted 1:200 in 1% normal goat serum (NGS), 0.1% TX-100 in PBS 
and incubated overnight at 4°C. Sections were washed three times with PBS, incubated with 
Alexa 488-conjugated anti-rabbit secondary antibody (Invitrogen) diluted 1:100 in 1% NGS 
TX-100, washed three times and mounted with Prolong Gold anti-fade with DAPI.  
Fluorescence staining was visualised using the Axioplan microscope (Zeiss). Images were 
captured using Axiovision Rel. 4.0 software. The Axiovision software linear measuring tool 
was used to analyse the spread (in m) of basement membrane surrounding blood vessels. 
 
Pericyte association 
For analysis of pericyte coverage, tumour sections were double immunostained for 
endomucin and NG2 (for details see Immunostaining of tumour sections). Pericyte coverage 
was quantified by counting the total number of endomucin positive blood vessels across 
whole tumour sections followed by the numbers of blood vessels positive for both endomucin 
and NG2. The percentage (%) of blood vessels with associated pericytes was calculated. 
 
Tumour blood vessel leakage 
To analyse tumour blood vessel leakage, Hoechst dye (4 g/ml; Sigma, H33258) was used. 
Hoechst dyes diffuse quickly from vessels and binds to the DNA of cells surrounding blood 
vessels, allowing for quantitation of areas of uptake by perivascular tumour cells and hence 
blood vessel leakage (Janssen et al., 2005). Briefly, mice were injected sequentially with 100 
μl PE-CD31 (Biolegend; to stain functional blood vessels) followed 9 min later with 100 μl 
Hoechst (4 g/ml; Sigma, H33258) via the tail vein and 1 min later culled. Tumours were 
excised and snap frozen. 8-10 fields at x20 magnification were analysed by ImageJ™. For 
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quantitation, blood vessel leakage was calculated by counting the numbers of Hoechst 
positive nuclei surrounding PE-CD31 positive tumour areas. Results are shown in arbitrary 
units (AU).  
 
Tumour growth and angiogenesis 
The syngeneic mouse tumour cell lines B16F0 (melanoma, derived from C57BL6) and Lewis 
Lung Carcinoma (LLC) (both from ATCC) were used in subcutaneous tumour growth 
experiments. 1x106 B16F0 cells or 0.5x106 LLC cells, resuspended in 100 l of phosphate 
buffered saline (PBS), were injected subcutaneously into the flank of 12-14 week old 
pdgfrcre+;6fl/fl and littermate control mice (pdgfrcre-;6fl/fl mice). Tumour growth was 
measured every 2 days using calipers. After 14 days, animals were culled, tumours excised 
and either fixed in 4% formaldehyde in PBS overnight, or snap-frozen in liquid nitrogen, for 
subsequent immunohistochemical analysis.  
 
Blood vessel density 
Size-matched tumours from pdgfrβcre-;6fl/fl and pdgfrβcre+;6fl/fl mice were snap-frozen 
and bisected, and cryosections made. Frozen sections were fixed in 100% acetone at −20°C, 
rehydrated in PBS for 10 min, and then blocked (PBS, 1% BSA, 0.1% Tween-20) for 45 min 
at room temperature. After a 5 min wash in PBS, sections were incubated with 1:100 anti-
endomucin in blocking buffer for 45 min at room temperature. After three 5 min washes in 
PBS, sections were incubated with Alexa 488-anti-rat secondary antibody (Invitrogen) diluted 
in blocking buffer. After three 5 min washes in PBS, sections were washed briefly with 
distilled water before being mounted. The number of endomucin-positive blood vessels 
present across the entire area of each mid-line tumour section from size and age-matched 
tumours was counted and divided by the area of the section to determine tumour blood vessel 
density. 
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Tumour blood vessel diameter 
The diameter of endomucin-positive blood vessels were quantified using the Axiovision™ software 
linear measuring tool. 
 
Perfused blood vessel analysis 
For analysis of the % of perfused, functional tumour vessels, 100 μl PE-CD31 antibody 
(Biolegend, London, UK) was injected via the tail vein 10 minutes (mins) prior to culling 
mice. Tumours were dissected immediately, snap frozen and sectioned. Frozen sections were 
then immunostained for endomucin as described above. To calculate the % number of 
functional vessels, the number of PE-CD31-positive blood vessels was divided by the total 
number of endomucin-positive blood vessels.  
 
Tumour metastasis 
0.5 x 106 LLC tumour cells were injected subcutaneously and tumours were allowed to reach 
a size of 100 mm3 before surgical resection. The mice were monitored for up to 3 weeks, after 
which the metastatic burden quantified by counting numbers of surface lung metastases. 
Lungs were then fixed and sections stained with H&E for further analysis. The numbers of 
surface metastases was counted immediately after fixation, to give the total number of lung 
metastases per mouse. To examine internal metastases, H&E stained sections were analysed 
and the area of individual metastases was measured using Axiovision™ software, to give the 
internal metastatic nodule area. 
 
Primary endothelial cell, fibroblast and pericyte isolation 
Primary mouse endothelial cells were isolated from lungs and maintained as described 
previously (Reynolds and Hodivala-Dilke, 2006). Briefly, pdgfrcre-;6fl/fl and 
pdgfrcre+;6fl/fl mouse lungs were minced, collagenase digested (Type I, Gibco), strained 
through a 70 m cell strainer (BD Falcon) and the resulting cell suspension plated on flasks 
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coated with a mixture of 0.1% gelatin (Sigma), 10g/ml fibronectin (Millipore) and 30g/ml 
rat tail collagen (Sigma). Endothelial cells were purified by a single negative (FC sort-
RII/III; Pharmingen) and two positive cell sorts (ICAM-2; Pharmingen), using anti-rat IgG-
conjugated magnetic beads (Dynal). During preparation of primary endothelial cells, lung 
fibroblasts were isolated from the non-endothelial cell population that was generated during 
the first positive sort. For all cell types, passaging occurred when cells reached 70% 
confluency. Cells were trypsinised, centrifuged, washed with PBS and replated on pre-coated 
flasks for endothelial cells and pericytes and non-coated flasks for fibroblasts. Fibroblasts 
were cultured in DMEM + 10% FCS to passage 4, Endothelial cells in MLEC (Ham’s F-12, 
DMEM (low glucose), 10% FCS, heparin and endothelial mitogen (Generon)) to passage 4-5. 
Pericytes were isolated from mouse brains as described previously (Tigges et al., 2012) and 
cultured in Pericyte medium (ScienCell) to passage 9. 
 
FACS analysis 
Primary mouse brain pericytes isolated from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice 
were incubated with an anti-6-integrin subunit antibody (GoH3; Abcam) to determine 
expression levels, for 30 min at 4°C. This was followed by incubation, for 30 min at 4°C with 
an appropriate FITC-conjugated secondary antibody. Unstained cells were used as a control. 
For characterisation of primary mouse brain pericytes, cells were washed with PBS and 
trypsinised at 37°C. The cell suspensions were washed in medium containing serum and 
centrifuged at 1, 200 rpm for 3 min. Cells were washed with cold FACS buffer (1% 
BSA/PBS) and fixed with 4% formaldehyde for 10 min at room temp. Cells were washed 
with FACs buffer and the cell suspensions were incubated with the following primary 
antibodies: PE-anti CD31 (Biolegend), PE-anti Mac1 (CD11b) (Biolegend),PE-anti GFAP 
(BD Biosciences), APC-anti PDGFR (Biolegend), PE-Cy7-anti CD146 (Biolegend) for 30 
min. Cells were then washed three times in sample buffer and resuspended in a final volume 
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of 400 ml. As a control, unstained cells were FACS sorted. Primary mouse lung endothelial 
cells were incubated with PE-anti CD31 (Biolegend). 
 
Western blot analysis 
Primary lung endothelial cells, lung fibroblasts and brain pericytes isolated from pdgfrcre-
;6fl/fl and pdgfrcre+;6fl/fl mice were grown to 70-80% confluency then lysed in RIPA 
buffer. 15-30 g protein was run on 8% polyacrylamide gels then transferred to nitrocellulose 
membranes. Membranes were probed with primary antibody overnight at 4°C. All antibodies 
(ERK, AKT, 6-integrin) for the signalling studies were purchased from Cell Signaling and 
used at a 1:1000 dilution. 3-integrin antibody was purchased from Millipore (AB1920). The 
anti-HSC70 antibody, used as a loading control, was from Santa Cruz and used at 1:5000 
dilution. For PDGF-BB stimulation, pericytes were serum starved for 6 h in Optimem with 
0.5% FCS, then stimulated with PDGF-BB (30 ng/ml; Peprotech, UK) for 0, 30 s, 60 s, 5 min, 
15 min, 30 min before lysis. Densitometric readings of band intensities were obtained using 
the ImageJ™ software. 
 
PDGFR immunostaining of cells 
Immunostaining of brain pericytes, isolated from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl 
mice for PDGFR (28E1, Cell Signaling), was performed according to the manufacturers’ 
protocol. 
 
Aortic ring assay 
Thoracic aortas were isolated from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl 8-10 week old 
mice and prepared for culture as described previously (Baker et al., 2012). Where indicated, 
culture medium was supplemented with PDGF-BB at 30 ng/ml (Peprotech, London, UK). 
PBS was used as a control. Rings were fed every 3 days with fresh medium with or without 
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PDFG-BB (30 ng/ml). Sprouting microvessels were counted after 9 days in culture, fixed and 
stained to identify endothelial cells and pericytes, as described previously (Baker et al., 2012). 
 
Scratch wound assays 
Primary mouse brain pericytes from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice were 
grown to confluency in Pericyte medium (ScienCell, CA. Cat no. 0010) in 6-well plates 
coated with 0.1% gelatin and fibronectin. Cells were serum starved overnight in Optimem 
containing 0.5% FCS. The following day, the monolayers were scratched horizontally and 
vertically through the centre of each well. The cells were either stimulated with PDGF-BB 
(30 ng/ml) or not and cell migration monitored over a 72 h period. At each timepoint, 12 
photographs were taken of each scratch and the wound width was measured using ImageJ™ 
software. Results were normalised to time 0. 
 
Proliferation assay 
Primary WT and 6-null brain pericyte proliferation was assessed using the CellTiter 96® 
Aqueous One Solution Reagent (Promega), according to the manufacturer’s instructions. 
Plates were read at a wavelength of 490 nm, with absorbance measured relative to blank wells 
containing reagent only. Plates were coated with 0.1% gelatin and fibronectin prior to seeding 
the pericytes.  
 
Characterising transgenic mice 
The primers for the Cre PCR were forward primer: 5-
GCCGCATTACCGGTCGATGCAAGA-3; reverse primer: 5-
GTGGCAGATGGCGCGGCAACACCATT-3. The reaction generates a fragment of 
approximately 1000 bp. The primers for 6-floxed PCR were forward primer: 5-
AGAAGGTGATGTTACCCT-3 and reverse primer: 5-AATGTAACTAGCATTCAAGT-3. 
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The PCR reaction generates a 154 bp fragment for the α6-ﬂoxed allele and a 120 bp fragment 
for the wild-type allele (described in Germain et al.).  
 
Whole-mount immunofluorescence on retinas 
Postnatal day (P) 9 eyes were fixed in 4% PFA overnight at 4C. Retinas were dissected in 
PBS and, after 5 washes in PBS, incubated in blocking solution (1% FBS (Sigma), 3% BSA 
(Sigma), 0.5% Triton X-100 (Sigma), 0.01% Na deoxycholate (Sigma), 0,02% Na Azide 
(Sigma) in PBS, pH7.4) for 2 h at room temperature. Retinas were incubated for overnight at 
4C with primary antibodies: rabbit polyclonal anti-NG2 (Millipore, #AB5320, dilution 
1:500) in blocking solution:PBS (1:1) overnight at 4C. Retinas were then washed several 
times in PBS and incubated with secondary antibody AlexaFluor 488 and AlexaFluor 548 
conjugates (Life Technologies), all diluted 1:300, overnight at 4C. After several washes in 
PBS, retinas were post-fixed in 1% PFA and re-blocked in 1%BSA/0.5% Triton X-100 in 
PBS for 1 hr at room temperature. After 2 rinses in PBlec (0.1 nM CaCl2, 0.1 MgCl2 mM, 
0.1 MnCl2 mM, and 1% Triton X-100 in PBS; pH6.8), retinas were incubated with 
biotinylated Isolectin B4 (B1205, VectorLabs, dilution 1:12.5) in PBlec overnight at 4C. 
After several washes in PBS, retinas were incubated with Streptavidin Alexa Fluor 647 
conjugate diluted 1:100 in 0.5%BSA/0.3% Triton X-100 in PBS overnight at 4C. After 
several washes in PBS, retinas were incubated with Hoechst dye as a nuclear counterstain 
(Life Technologies), washed and mounted with ProLong Gold (Molecular Probes). 
Fluorescently labelled samples were imaged with a confocal microscope (Carl Zeiss LSM 710, 
Carl Zeiss) in multichannel mode. Three-dimensional projections were digitally reconstructed 
from confocal z-stacks using the LSM Zen 2009 software and Image J open source image 
processing software (version:2.0.0-rc-43/1.51d). 
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Adhesion assay 
Adhesion assays were performed as previously described (Germain et al., 2010), using brain 
pericytes isolated from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice. Adhesion of pericytes 
is presented relative to adhesion of pericytes to fibronectin for the same genotype. 
 
Immunostaining of immune cells, fibroblasts and endothelial cells 
Immunostaining of immune cells from B16F0 tumour sections was performed as described 
previously (Reynolds et al., 2010). 
 Primary mouse lung fibroblasts and endothelial cells were fixed with 4% PFA for 10 min, 
washed twice and blocked with 5% NGS in PBS for 30 min at room temperature. Primary 
antibodies to vimentin (1:100; Cell Signaling), NG2 (1:100; MAB 5385, Millipore), 
endomucin (1:100; V7C7, Santa Cruz) and -sma (clone 1A4, Sigma) were incubated for 1 h 
at room temperature, washed three times with PBS, and incubated with the relevant secondary 
antibody for 45 min at room temperature.  
 
Reverse phase protein array (RPPA) Nitrocellulose slides 
Cell lysates were prepared using ice cold RIPA buffer. After normalization, to adjust protein 
concentrations, triplicate spots of each lysate were deposited onto16-pad Avid Nitrocellulose 
slides (Grace Bio) under conditions of constant 70% humidity using an Aushon 2470 Array 
platform (Aushon BioSystems). After printing and washing steps, the arrays were blocked by 
incubation in Superblock (Thermo Scientific #37535) for 10 min. The protein array chips 
were subsequently incubated for 1 h with primary antibody followed by repeat blocking with 
Superblock and 30 min incubation with anti-rabbit Dylight-800 conjugated secondary 
antibody (Cell Signaling, cat.no.5151).  
Following secondary antibody incubation and subsequent wash steps the immune-stained 
arrays were imaged using an Innopsys 710IR scanner (Innopsys France). Microarray images 
were obtained at the highest gain without saturation of fluorescent signal detection. Image 
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analysis was performed using Mapix software (Innopsys France) to calculate the relative 
fluorescence intensity (RFI) value for each sample.  An estimate of total protein printed per 
feature on the array was determined by staining an array slide with fastgreen protein stain. 
Readout values for all antibodies tested are expressed as a ratio of total protein loaded and are 
presented as the mean of technical replicates. 
 
Statistical analysis 
Statistical significance was calculated using Student's t-test. p <0.05 was considered 
statistically significant. 
 
Ethical regulations 
All animals were used in accord with United Kingdom Home Office regulations (Home 
Office license number 70/7449). The in-house Ethics Committee at Queen Mary University 
of London has approved all experiments, using mice under the project license. 
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Results 
Generation and characterisation of pdgfrcre+;6fl/fl mice 
We have generated a new mouse model that enables us to study deletion of 6-integrin in 
pericytes. We bred 6-integrin floxed mice (Bouvard et al., 2012, Germain et al., 2010) with 
mice expressing Cre-recombinase under the control of the Platelet Derived Growth Factor 
Receptor  (PDGFR) promoter, PDGFRCre (Foo et al., 2006), to generate pdgfrβcre-
;6fl/fl and pdgfrβcre+;6fl/fl mice. Mice were born to pdgfrβcre+;6fl/fl x pdgfrβcre-
;6fl/fl crosses at normal Mendelian ratios and male:female ratios with no obvious adverse 
phenotype (Fig. S1A-C). Mice were genotyped by PCR analysis (Fig. S1D). Histological 
analysis of H&E-stained sections of lung, heart, liver and spleen from pdgfrβcre-;6fl/fl and 
pdgfrβcre+;6fl/fl adult mice showed no apparent tissue defects (Fig. S1E). Furthermore, no 
apparent vascular abnormalities were observed in these tissues (Fig. S1F) or in the 
developing retina (Fig. S1G), suggesting that loss of PDGFR-driven 6 had no apparent 
effect on physiological angiogenesis. Finally, to confirm pericyte specific Cre expression in 
our mouse model, we crossed pdgfrβcre- and pdgfrβcre+ mice with the mTmG reporter 
mouse (Muzumdar et al., 2007). Analysis of tumour blood vessels from pdgfrβcre-;mTmG 
and pdgfrβcre+;mTmG mice showed that although tomato (mT) expression was observed in 
blood vessels in both pdgfrβcre-;mTmG and pdgfrβcre+;mTmG mice, GFP (mG) expression, 
was present in mouse tissue only after Cre excision, and only observed in pericytes in 
pdgfrβcre+;mTmG mice (Fig. S2A, B). As expected, 6-integrin is expressed on tumour 
endothelial cells, shown by co-expression of 6-integrin and the endothelial cell marker 
CD31 (Fig. S2C), suggesting that the deletion of 6-integrin in vivo was restricted to 
PDGFR-positive pericytes. 
 
6-integrin deficiency on pericytes impairs tumour blood vessel stabilisation 
Very few studies have examined the role of pericyte integrins in tumour blood vessels in vivo 
(Garmy-Susini et al., 2005, Turner et al., 2014, Liu and Leask, 2012). To assess whether 6-
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integrin is required for pericyte investment on blood vessels during tumour angiogenesis, 
pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice were injected with either syngeneic B16F0 
melanoma or LLC tumour cells. We first established loss of 6-integrin expression in 
pericytes in tumour blood vessels from pdgfrcre+;6fl/fl mice. Tumour sections from 
pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl were double stained for NG2 (a pericyte marker) 
and 6-integrin. Although 6-integrin was expressed in NG2 positive pericytes in tumour 
blood vessels in pdgfrcre-;6fl/fl control mice, 6-integrin was undetectable in pericytes 
from pdgfrcre+;6fl/fl mice (Fig. 1A) confirming that 6-integrin expression is reduced on 
pericytes in tumours grown in pdgfrcre+;6fl/fl mice. Quantification revealed a significant 
reduction in 6-integrin expression in NG2-positive pericytes in tumour blood vessels from 
pdgfrcre+;6fl/fl mice (Fig. 1B). Having confirmed deletion of 6-integrin in pericytes in 
tumour blood vessels from pdgfrcre+;6fl/fl mice in vivo, we asked whether PDGFR 
driven 6-integrin deletion could affect pericyte association with tumour blood vessels. A 
significant reduction in the number of pericytes associated with blood vessels in B16F0 and 
LLC tumours grown in pdgfrcre+;6fl/fl mice was observed (Fig. 1C). Thus, the absence of 
6-integrin corresponds with a reduction in pericyte association with blood vessels.  
 
Blood vessel leakage is enhanced in tumours from pdgfrcre+;6fl/fl mice 
We next examined other possible biological consequences of the loss of pericyte 6-integrin. 
We found that reduced pericyte investment correlated with a higher frequency of blood 
vessels with a large diameter (>100 m), in tumour blood vessels from pdgfrcre+;6fl/fl 
mice (Fig. 1D). A known result of increased blood vessel diameter is poor functionality of 
blood vessels (Huang et al., 2010). We therefore examined tumour blood vessel leakage by 
measuring the relative level of perivascular Hoechst after intravenous injection of Hoechst 
dye. Blood vessel leakage was calculated by counting the numbers of Hoechst positive nuclei 
surrounding tumour blood vessels. Tumour blood vessels from pdgfrcre+;6fl/fl mice 
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showed significantly more leakage of Hoechst dye than from pdgfrcre-;6fl/fl mouse 
tumours (Fig. 1E). Together, these data demonstrate that loss of pericyte 6-integrin is 
sufficient to reduce pericyte coverage of tumour blood vessels and increase vessel diameter 
and leakage. 
 
Blood vessel basement membrane organisation is altered in tumours grown in 
pdgfrcre+;6fl/fl mice 
Given that extracellular matrix (ECM) deposition is a crucial step in the maturation of tumour 
blood vessels, and requires the presence of both pericytes and endothelial cells, we examined 
whether the distribution of various BM matrices correlated with the observed decrease in 
pericyte tumour blood vessel association in pdgfrcre+;6fl/fl mice. Concomitant with 
reduced vascular stabilisation and increased leakiness in the pdgfrcre+;6fl/fl tumour blood 
vessels, a higher frequency of disorganised BM around tumour blood vessels was seen in 
pdgfrcre+;6fl/fl mice. Specifically, immunofluorescence analysis of collagen IV (Fig. 2A), 
fibronectin (Fig. 2B), laminins 5- (Fig. 2C) and 4-chains (Fig. 2D) in the BM around 
tumour blood vessels, revealed a “shorelining” pattern of BM components (DiPersio et al., 
1997) in pdgfrcre+;6fl/fl mice. Quantification confirmed that the BM was wider with 
aberrant organisation, in blood vessels from pdgfrcre+;6fl/fl mice than from pdgfrcre-
;6fl/fl mice (Fig. 2E). Adhesion assays, using mouse primary pericytes showed, as expected, 
that the absence of 6-integrin reduced significantly the adherence to Laminin 111 (Lm-1), 
but not fibronectin (Fig. S3A).  
Since blood vessel stabilisation is a consequence not only of BM deposition but the 
association of supporting cells, ie. pericytes, these results show that pericyte investment and 
the formation of a normal BM is affected by deletion of pericyte 6-integrin, and likely 
contributes to the abnormal stability and leakage of tumour blood vessels in 
pdgfrcre+;6fl/fl mice. 
 
 18 
Depletionof pericyte 6-integrin does not affect tumour growth or metastasis 
Despite the dramatic changes in pericyte association, vessel leakage and BM architecture, no 
significant difference in tumour growth (Fig. 3A), blood vessel density (Fig. 3B), numbers of 
functional blood vessels (Fig. 3C), metastasis (Fig. 3D) or immune cell infiltrate (Fig. S3B) 
was observed between pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice. These data suggest 
that the changes in blood vessels observed in pdgfrcre+;6fl/fl mice is not sufficient to 
affect tumour growth, angiogenesis or metastasis. 
 
6-integrin controls pericyte PDGFR expression  
In mice, genetic ablation of PDGF-BB and PDGFR leads to various vascular abnormalities 
associated with pericyte loss, including a loss of pericyte association to blood vessels 
(Abramsson et al., 2003). Since PDGF-BB is one of the major growth factors involved in 
pericyte investment to blood vessels (Abramsson et al., 2003, Furuhashi et al., 2004) we 
sought to investigate whether loss of 6-integrin affected pericyte responses to PDGF-BB. 
Initially, primary pericytes, fibroblasts and endothelial cells were isolated from pdgfrcre-
;6fl/fl and pdgfrcre+;6fl/fl mice and characterised (Fig. S4A-C). Western blot analysis 
and FACS confirmed deletion of 6-integrin only in pericytes (Fig. 4A). This loss of 6-
integrin was not compensated for by the overexpression of another laminin receptor, the 3-
integrin subunit in 6-null pericytes (Fig. 4B). Further Western blot analysis showed that 6-
integrin levels were normal in fibroblasts and endothelial cells isolated from pdgfrcre-
;6fl/fl and pdgfrcre+;6fl/fl mice (Fig. 4C). The loss of 6-integrin in pericytes correlated 
with an approximately two-fold reduction in levels of PDGFR in 6-null pericytes, 
suggesting that 6-integrin was indeed regulating the expression of PDGFR protein (Fig. 
4D). Additionally, PDGFR levels were significantly reduced in PDGFR immunostained 
6-null pericytes compared with WT pericytes in vitro (Fig. 4E).  
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PDGF-BB responses are diminished in 6-null pericytes 
Since changes in receptor expression levels do not always reflect changes in downstream 
signalling of the corresponding tyrosine kinase receptor (Platta and Stenmark, 2011), we next 
sought to confirm whether the decreased expression of PDGFRcorrelated with diminished 
responses to PDGF-BB stimulation in 6-null pericytes. We showed that PDGF-BB 
stimulated ex vivo microvessel sprouting was reduced in aortic rings isolated from 
pdgfrcre+;6fl/fl mice compared with PDGF-BB stimulated sprouting from pdgfrcre-
;6fl/fl mouse aortic rings (Fig. 5A). In this assay the vessel sprouts become surrounded by 
pericytes which proliferate and migrate along the endothelium (Nicosia, 2009). We were 
unable to analyse pericyte coverage in pdgfrcre+;6fl/fl aortic rings due to the complete 
lack of sprouts that grew in response to PDGF-BB. In response to PDGF-BB, 6-null 
pericyte migration and proliferation was significantly reduced when compared with WT 
controls (Fig. 5B, C). We next examined the effect of 6-deficiency on PDGF-BB stimulated 
downstream signalling in pericytes. Interaction of PDGFR with PDGF-BB activates several 
signalling pathways, including MAP Kinase (ERK) and PI3K/AKT. Western blot analysis 
showed that, in 6-null pericytes, PDGF-BB mediated stimulation of ERK and AKT 
pathways were both reduced significantly (Fig. 5D, E). Since integrins and PDGFR can 
activate many downstream signalling pathways, we performed a non-candidate proteomic 
study using Reverse Phase Protein Array (RPPA) analysis, to identify other possible 
pathways that may be affected by the absence of 6-integrin on pericytes. We found that 
components of the AKT/mTOR signaling pathway (AKT, P70 S6kinase, mTOR, pS6 
ribosomal protein and 4E-BP1) were significantly downregulated in 6-null pericytes (Fig. 
S4D). This pathway is activated downstream of integrins and is known to be regulated by 
PDGFR expression and function (Zhang et al., 2007). These results suggest that absence of 
6-integrin results in a reduction of PDGFRlevelssignificantly reducing pericyte responses 
to PDGF-BB. 
Collectively, these results demonstrate a novel role for pericyte 6-integrin in both the 
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regulation of PDGFR levels that was previously unknown, and in BM organisation. This 
dual mechanism confers a blood vessel phenotype that affects only the primary tumour. 
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Discussion 
The role of pericyte 6-integrin expression has not been addressed previously. We have now 
shown that, the combined effects of the down-regulation of PDGFR and the changes in 
pericyte adhesion, upon deletion of 61-integrin, induces destabilisation of tumour blood 
vessels. Genetic ablation of pericyte 61-integrin correlates with reduced pericyte 
investment to tumour blood vessels, changes in BM architecture and reduced PDGFR 
expression levels and PDGF-BB-mediated downstream signalling. These correspond with 
increased blood vessel leakage without affecting tumour growth or metastasis. Together, our 
results suggest a dual function of 6-integrin on pericytes and here we will discuss both the 
effect of reduced PDGFR levels and decreased pericyte adhesion in turn.  
 
Very few studies have linked pericyte integrins with growth factor receptor regulation.  
Currently, 51 integrin has been shown to regulate signalling through PDGFR in vascular 
smooth muscle cells (Veevers-Lowe et al., 2011), and inactivation of PDGF-BB signalling 
can decrease 11 integrin levels (Hosaka et al., 2013). In another study, NG2 depletion in 
pericytes was shown to reduce 1-integrin-mediated signalling (You et al., 2014). Although 
limited, these studies suggest possible cross-talk between pericyte integrins and growth factor 
receptors; a mechanism that has been shown previously between endothelial cell integrins and 
growth factor receptors (da Silva et al., 2010, Germain et al., 2010, Reynolds et al., 2002). In 
parallel, in vitro studies using fibroblasts have highlighted the ability of integrins to enhance 
PDGF-dependent responses (DeMali et al., 1999, Sundberg and Rubin, 1996). Here we show 
for the first time that 61-integrin acts as a regulator of PDGFR – controlling its 
expression and signalling upon stimulation with PDGF-BB, in pericytes. Our data indicate 
that depletion of 6-integrin on pericytes leads to a significant reduction in the levels of 
PDGFR. In turn, this leads to a downregulation in the activation of the MAPKinase and 
AKT signalling pathways, which are both known to be critical for cell migration and 
proliferation (Lemmon and Schlessinger, 2010).  Our observation of reduced pericyte 
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PDGFR levels, signalling and resulting inhibited responses to PDGF-BB, in 6-integrin 
deficient pericytes, may explain the tumour blood vessel phenotypes we observe in the 
pdgfrcre+;6fl/fl mice; including reduced pericyte blood vessel investment and increased 
detachment of pericytes to endothelial cells, since these functions have been reported to be 
mediated by PDGF-BB (Abramsson et al., 2003, Hellberg et al., 2010). It has been well 
documented that tumours transplanted into PDGF-B retention motif-deficient (pdgf-bret/ret) 
mice have an approximately 50% reduction in numbers of pericytes that poorly associate with 
the blood vessel wall and result in leaky vessels (Abramsson et al., 2003). It is noteworthy 
that although we observe a similar leaky blood vessel phenotype to that reported in tumour 
growth in pdgf-bret/ret mice, our results indicate that 61 integrin is a regulator of pericyte 
function rather than numbers, as seen in the pdgf-bret/ret mice (Lindblom et al., 2003). 
 
One surprising observation was that despite such striking blood vessel defects in the 
pdgfrcre+;6fl/fl mouse tumours, including increased vessel leakage, we did not observe 
any changes in tumour growth, angiogenesis or lung metastasis (Cooke et al., 2012, Zang et 
al., 2015). Our work is in line with previous studies showing that early ablation of NG2+ cells 
or PDGFR+ pericyte depletion does not necessarily affect tumour growth and metastasis 
(Keskin et al., 2015) suggesting that increased leakage alone is not sufficient to enhance 
metastasis. Indeed, increased vascular leakage has been shown to be insufficient for 
metastasis per se (Thurston et al., 1999). We hypothesise that despite the observed decrease 
in blood vessel pericyte coverage in pdgfrcre+;6fl/fl mice, the remaining pericytes 
attached to the endothelial cells provide enough survival factors, for example VEGF and Ang-
1, to allow ECs to survive, allowing for normal tumour angiogenesis and tumour growth. 
Studies have shown that decreased PC coverage can lead to regression of blood vessels but 
the magnitude is tumour specific and does not necessarily retard tumour growth (Sennino et 
al., 2007). Indeed, treatment of RipTag2 tumours with anti-PDGFR antibody reduces 
pericyte numbers and enlarges blood vessels but does not reduce tumour vascular density 
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(Song et al., 2005). Although not within the scope of this study, we believe that the phenotype 
observed in our pdgfrcre+;6fl/fl mice may help to improve chemotherapy efficacy to 
primary tumours, due to the leaky vessel defect.  
 
As well as pericyte 6-integrin deficiency affecting PDGFR levels and upstream signalling, 
we also show that deletion of 6-integrin affects the ECM adhesion properties of pericytes in 
vitro and in vivo. The BM that surrounds blood vessels is necessary for vessel integrity, 
stability and maturation. Recent studies have highlighted the importance of normal 
endothelial cell-pericyte interactions for proper BM organisation (Davis et al., 2013, Stratman 
et al., 2009, Baluk et al., 2003). When this interaction is de-stabilised, BM organisation is 
affected, resulting in decreased vessel integrity (Stratman et al., 2009, Davis et al., 2013). 
Therefore, it is possible that the phenotype we observe in the microvessel BM of 
pdgfrcre+;6fl/fl mice may be due, at least in part, to a loss of pericyte adhesion to 
endothelial cell basement membrane. Similar phenotypes have been shown in other studies, 
for example: inactivation of the 1-integrin subunit in mural cells leads to failure of these 
cells to associate with the subendothelial BM (Abraham et al., 2008); genetic ablation of a 
related laminin receptor, 3-integrin results in an epidermal BM defect, in which components 
of the BM show a disorganised expression pattern (DiPersio et al., 1997, Georges-Labouesse 
et al., 1996, Has et al., 2012) very similar to that observed in tumour blood vessels of 6-
integrin pericyte deficient mice.  Foxf2 (forkhead transcription factor, specifically expressed 
by pericytes) deficiency in brain pericytes leads to significantly reduced PDGFR and v8 
integrin levels with thinning of the vascular basal lamina, resulting in a leaky blood brain 
barrier (Reyahi et al., 2015); inactivation of PDGF-BB signalling decreases 11 integrin 
levels and impairs pericyte adhesion to extracellular matrix components of blood vessels 
(Hosaka et al., 2013).  
Together these studies all support a common notion that crosstalk between pericyte integrins 
with PDGFR signalling can affect vascular BM organisation and vessel function. It is also 
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conceivable that microvessel BM disorganisation may be a contributing cause of decreased 
supporting cell coverage in the tumour blood vessels in pdgfrcre+;6fl/fl mice. For 
example, it has been shown that deletion of laminin-4 chain in mice causes impaired vessel 
growth due to reduced pericyte recruitment to blood vessels (Abrass et al., 2010). In vitro, 
pericyte recruitment during tube formation is necessary to stimulate endothelial BM 
formation (Stratman et al., 2009). Overall, our data suggest that the absence of pericyte 6-
integrin leads to i) the reduced investment of pericytes to tumour microvessels possibly due to 
reduced PDGFR levels, and ii) this is associated with poor vessel BM architecture leading to 
vascular leakage. 
 
Our study provides new insights into the regulation of tumour blood vessels by pericyte 6-
integrin which points towards an important role in the regulation of tumour vessel leakage. 
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Figure Legends 
 
Figure 1. Reduced pericyte investment and increased vessel leakage in pdgfrcre+;6fl/fl 
mice. 
(A) B16F0 tumour sections from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice were 
double-immunostained for NG2 (red) and 6-integrin (green) expression to determine in vivo 
expression of 6-integrin in pericytes. 6-integrin was observed in NG2-positive  pericytes in 
tumour blood vessels from pdgfrcre-;6fl/fl mice. In contrast, 6-integrin expression was 
significantly reduced in pericytes in tumour blood vessels from pdgfrcre+;6fl/fl mice. 
Magnified regions show 6-integrin positive pericytes (to give a yellow signal) on pdgfrcre-
;6fl/fl blood vessels but 6-integrin negative pericytes on pdgfrcre+;6fl/fl blood vessels. 
Arrows, 6/NG2 co-expression; arrowheads, NG2 expression alone. (B) Quantitation of 6-
integrin expression in NG2-positive pericytes from tumour blood vessels in pdgfrcre-;6fl/fl 
in pdgfrcre+;6fl/fl mice. Bar chart represents mean pixel intensity of 6-integrin 
expression in NG2-positive cells+SEM; n=9-10 tumours per genotype. (C) Pericyte 
association with blood vessels. The % of blood vessels with associated NG2-positive 
pericytes in B16F0 and LLC tumours grown in pdgfrcre+;6fl/fl mice was reduced 
significantly compared with pdgfrcre-;6fl/fl mice. Scatter graphs represent % blood vessels 
that are NG2-positive in B16F0 and LLC tumours+SEM; n= 4-6 mice/group. Representative 
images of tumour sections stained with the pericyte marker, NG2 (green) and endomucin 
(red). Arrows, endomucin positive staining; arrowheads, NG2 positive staining. (D) Blood 
vessel diameter. The frequency of vessels with a diameter ≥100 m was greater in both 
B16F0 and LLC tumours grown in pdgfrcre+;6fl/fl mice when compared with pdgfrcre-
;6fl/fl mice. Bar charts represent the % of blood vessels ≥100 m diameter+SEM. (E) Blood 
vessel leakage. Mice were injected via the tail vein with Hoechst dye and tumour sections 
were analysed for blood vessel leakage by measuring the numbers of tumour cells that had 
taken up Hoechst. Blood vessels in the tumours grown in pdgfrcre+;6fl/fl mice showed 
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significantly more leakage than blood vessels in tumours grown in pdgfrcre-;6fl/fl mice. 
Bar chart shows relative Hoechst leakage+SEM; n= 6 tumours/genotype. Dotted lines, 
Hoechst leakage. *p <0.05, **p <0.005, ***p <0.0009. Scale bar in A= 50 m, C= 100 m 
and E= 200 m. 
 
Figure 2. Tumours grown in pdgfrcre+;6fl/fl mice have aberrant BM organisation 
around blood vessels. 
LLC tumours were stained with antibodies to the extracellular matrix proteins (A) collagen 
IV, (B) fibronectin, (C) laminin 5 and (D) laminin 4 chains. For all matrices, 
disorganisation of basement membrane with a “shoreline” pattern was observed more 
frequently around blood vessels in tumours grown in pdgfrcre+;6fl/fl mice when compared 
with pdgfrcre-;6fl/fl mice. (E) The width of the BM surrounding blood vessels was 
analysed. Boxes show magnified regions of BM. Brackets, identify representative BM widths. 
n= 8-10 sections/genotype; **p<0.005. Scale bars = 50 m. 
 
Figure 3. Tumour growth, angiogenesis and metastasis are not affected in 
pdgfrcre+;6fl/fl mice. 
(A) Subcutaneous B16F0 and LLC tumour growth was similar in both pdgfrcre+;6fl/fl 
mice and pdgfrcre-;6fl/fl mice. Bar charts represent mean tumour volumes±SEM; n=20-30 
mice/genotype. (B) Endomucin staining of midline sections of age- and size-matched B16F0 
and LLC tumours showed no significant differences in blood vessel density between 
pdgfrcre+;6fl/fl mice and pdgfrcre-;6fl/fl mice. Blood vessel density is given as the 
number of blood vessels/mm2 of midline tumour section. Representative images of 
endomucin stained tumour blood vessels are shown. Bar chart represents mean tumour blood 
vessel density of size-matched tumours+SEM; n= 6 tumour sections/genotype, ns=no 
significant difference. (C) The number of perfused tumour blood vessels was assessed by tail 
vein injection of PE-CD31 antibody before tumour excision in pdgfrcre+;6fl/fl mice and 
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pdgfrcre-;6fl/fl control mice and comparing the numbers of CD31-positive vessels with 
numbers of endomucin stained vessels. B16F0 and LLC tumours grown in pdgfrcre+;6fl/fl 
mice had a similar number of functional PE-CD31 endomucin expressing tumour blood 
vessels compared to pdgfrcre-;6fl/fl littermate control mice. Bar charts represent the 
percentage of PE-CD31 perfused vessels over total number of endomucin positive blood 
vessels per midline tumour section from pdgfrcre+;6fl/fl mice and pdgfrcre-;6fl/fl mice 
+ SEM; n=10 tumour sections per genotype, ns=no significant difference. Representative 
images of endomucin stained, PE-CD31 positive perfused blood vessels from B16F0 tumours 
are shown. (D) Metastasis is not affected in pdgfrcre+;6fl/fl mice. Subcutaneous LLC 
tumours were resected when they reached approximately 100 mm3. At 3 weeks post-resection 
mice were culled and lungs removed to assess metastasis. Lungs were fixed and the number 
of surface metastases was counted. There were no significant differences in the total number 
of surface metastases between pdgfrcre+;6fl/fl mice and pdgfrcre-;6fl/fl mice (bar 
chart). Lungs were then sectioned and stained with H&E. Measurement of individual 
metastatic nodule areas showed no difference between genotypes (scatter graph). 
Representative high power images of H&E stained lung sections show areas of metastasis 
(dotted line) (upper images) as well as low power images of metastatic lung tissue (arrows) 
(lower images). Scale bar in B= 100 m, C= 50 m, D= 50 m (upper panel), 5000 m 
(lower panel). 
 
Figure 4. Pericyte 6-integrin regulates PDGFR expression 
 (A) Pericytes were isolated from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice, and 
Western blot analysis performed to assess 6-integrin deletion. 6 deletion was only 
observed in pericytes from pdgfrcre+;6fl/fl mice. FACS analysis also confirmed loss of 
6-integrin surface levels in pericytes isolated from pdgfrcre+;6fl/fl mice compared with 
pericytes isolated from pdgfrcre-;6fl/fl mice (line graph and equivalent data dot plot). Bar 
charts represent densitometric readings of Western blots, corrected for loading. N=3 separate 
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lysates/genotype. (B) Western blot analysis confirmed that WT and 6-null pericytes have 
similar levels of 3-integrin, a second laminin receptor, suggesting that there was no 
compensation of 3-integrin in the absence of 6-integrin. N=3 separate lysates/genotype. 
(C) Fibroblasts and endothelial cells were isolated from pdgfrcre-;6fl/fl and 
pdgfrcre+;6fl/fl mice and Western blot analysis performed to assess 6-integrin levels. 
6-integrin levels were not affected in either cell type isolated from either pdgfrcre-;6fl/fl 
and pdgfrcre+;6fl/fl mice. (D) Western blot analysis revealed PDGFR protein levels were 
significantly reduced in primary 6-null pericytes. Bar chart shows densitometric values of 
PDGFR levels, corrected for loading. HSC70 was used as a loading control; n=3 separate 
lysates/genotype; *p <0.05; ns=no significant difference. (E) Immunostaining of PDGFR in 
6-null pericytes in culture was significantly reduced compared with WT pericytes. Scale bar 
in E = 50 m. 
 
Figure 5. Responses to PDGF-BB are reduced in 6-null pericytes 
(A) Aortic rings were isolated from pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice and 
treated with either PBS or PDGF-BB (30 ng/ml) for up to 10 days. PDGF-BB stimulation 
increased vessel sprouting in pdgfrcre-;6fl/fl but not pdgfrcre+;6fl/fl aortic rings. Bar 
charts show average number of aortic sprouts/genotype+SEM; n=40-50 rings/genotype in 
triplicate. (B) Confluent monolayers of primary WT and 6-null pericytes were wounded 
manually, after 24 h serum starvation, then stimulated, or not, with PDGF-BB (30 ng/ml). 
Wound width was quantified up to 48 h. Wound closure was significantly reduced in 6-null 
pericytes in response to PDGF-BB. Bar charts show wound width in the absence (left panel) 
or presence (right panel) of PDGF-BB, normalised to time 0; n=6/genotype/time point in 
triplicate.  (C) Proliferation of primary WT and6-null pericytes in the presence of Optimem 
or PDGF-BB was measured. 6-null pericytes proliferated significantly less in the presence 
of PDGF-BB compared with WT pericytes. Graphs represent relative proliferation; n=3 
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biological repeats. (D) Western blot analysis of phosphorylated-ERK1/2, total ERK1/2, 
phosphorylated-AKT and total AKT, from WT and 6-null pericyte lysates after serum 
starvation and stimulation with PDGF-BB for 0, 30 s, 60 s, 5 min, 15 min, 30 min. 
Downstream signalling responses to PDGF-BB in 6-null pericytes were reduced 
significantly. Individual cropped blots are representative of samples run on the same gel 
under identical experimental conditions. HSC70 acted as the loading control. (E) Graphs 
show densitometric readings of fold change of ratios p-AKT/totalAKT to time 0; fold change 
of ratios p-ERK1/2/totalERK1/2 to time 0±s.e.m. N=3 independent experiments. *p <0.05, 
**p <0.005.  
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Supplementary Figure 1. Characterisation of pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl 
mice and morphological analysis of tissue and postnatal retinal angiogenesis.  (A) 
Pdgfrcre-;6fl/fl mice crossed to pdgfrcre+;6fl/fl mice produce: litters that had a similar 
Supplementary Figure 1 Reynolds et al 
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number of pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice in predicted Mendelian ratios, (B) 
and similar ratios of pdgfrcre+;6fl/fl males and females, identified at weaning. (C) Mice 
were weighed at 3 months old. No differences were observed in the weights of sex-matched 
mice between the two genotypes. (D) All mice were analysed by PCR genotyping and shows 
a product identifying pdgfrcre+ PCR at approx. 1000 bp. 6-integrin-floxed PCR shows 
products identifying homozygous 6-integrin floxed (6fl/fl) (154 bp), WT non-floxed (6-
integrin wt) (120 bp), and heterozygous (6-integrin fl/wt) mice (154 bp and 120 bp). (E) 
Representative H&E stained sections of lung, heart, liver and spleen from 12 week old 
pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice. No gross morphological defects were 
observed. (F) Representative high power images of blood vessels in lung, heart and liver from 
pdgfrcre-;6fl/fl and pdgfrcre+;6fl/fl mice showed no obvious morphological blood 
vascular defects between the genotypes. (G) Confocal microscopy images show 3D Z-stack 
reconstructions of flat whole-mount immunofluorescent stained retinas from pdgfrcre-
;6fl/fl and pdgfrcre+;6fl/fl mice at postnatal day (P) 9. Arterial, vein and capillary vessels 
in the superficial retinal plexus are visualised with Isolectin B4 (IB4, green). Pericytes are 
identified with NG2 (red); n=4 retinas/genotype. Scale bar in E=20 m; F=100 m; G=50 
m. 
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Supplementary Figure 2. mTmG reporter activity in pericytes after PDGFRCre 
excision. mTmG mice are used as a reporter of Cre activity in Cre+ mice. We generated 
pdgfrcre-;mTmG and pdgfrcre+;mTmG mice. (A) Schematic representation of the mTmG 
reporter effect in pdgfrcre+ mice. In non-Cre expressing cells mT (red) signal is observed in 
endothelial cells (EC). In Cre expressing cells the mT transgene is excised and the mG 
Supplementary Figure 2 Reynolds et al 
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(green) signal is observed in pericytes (PC). (B) B16F0 tumour cells were injected 
subcutaneously into pdgfrcre-;mTmG and pdgfrcre+;mTmG mice and tumours excised 12 
days post inoculation. Tumour blood vessels were examined for expression of both 
membrane-targeted tandem dimer Tomato (mT) (red), seen in all host tissue and membrane-
targeted green fluorescent protein (GFP) (mG) (green). GFP expression was observed only in 
pdgfrcre+;mTmG mice, as expected and almost exclusively in PCs surrounding blood 
vessels (white box, magnified region). (C) Tumour blood vessels immunostained with 
antibodies to 6-integrin and CD31 revealed co-expression of the 2 markers, showing that 
6-integrin expression is not affected on endothelial cells in vivo. Scale bars in B, C =50 m. 
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Supplementary Figure 3. Adhesion of wild-type and 6-null pericytes to Laminin-1 and 
immune cell infiltration in tumours. 
(A) 5x104 wild-type (WT) and 6-null mouse brain pericytes were allowed to adhere to 
Laminin-1 (Lm-1; 10g/ml) and Fibronectin (Fn; 10g/ml) coated 96-well plates for 1 h at 
37°C. 6-null pericytes do not bind effectively to the Lm-1 matrix compared with WT 
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pericytes. No difference in Fn adhesion was observed between WT and 6-null pericytes. Bar 
chart represents % adhesion of pericytes to Lm-1 relative to adhesion to Fn for the same 
genotype. n=3 biological repeats; **p<0.01. Sections from tumours grown in pdgfrcre-
;6fl/fl and pdgfrcre+;6fl/fl mice were stained with antibodies to inflammatory cell 
markers (B) CD8 (T cells), (C) CD45 cells and (D) F480 (macrophages). No difference in 
inflammatory cell infiltration was observed between tumours from either genotype. Bar charts 
represent % immune cell infiltration; n=6 tumours/genotype;ns= not significantly different. 
Scale bar =100m. 
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Supplementary Figure 4. Characterisation of primary mouse brain pericytes, primary 
mouse lung endothelial cells and fibroblasts and Reverse Phase Protein Array (RPPA) 
analysis reveals the mTOR signalling pathway is attenuated in 6-null mouse brain 
pericytes. (A) Primary mouse brain pericytes were characterised using the following markers, 
by FACS: PDGFR, CD146, CD31 (endothelial marker), glial fibrillary acidic protein 
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(GFAP) and Mac1 (fibroblast markers). Red graph = unstained cells, blue graph = stained 
cells. The results are shown as a histogram (left) and dot plot (right). pdgfrcre-;6fl/fl mouse 
brain pericytes were also immunostained for NG2 (pericyte marker) and visualised by 
epifluorescence microscopy. (B) Primary mouse lung endothelial cells were stained for CD31 
followed by FACS analysis and immunostained for endomucin and vimentin (expressed by 
ECs) and -sma (fibroblast marker). (C) Primary mouse lung fibroblasts were immunostained 
for vimentin (positive marker for fibroblasts), NG2 and endomucin (negative markers for 
fibroblasts). Rat IgG was used as a negative control. (D) RPPA analysis of protein extracted 
from WT and 6-null periytes showed a significant reduction in many proteins in 6-null 
pericytes.  These included components of the mTOR signalling pathway – AKT, p70S6kinase, 
mTOR, pS6 ribosomal protein and 4E-BP1; this pathway is important for several cell 
functions including growth, migration, proliferation and angiogenesis and is known to be 
activated by integrins.   
